Metagenomi Therapeutics, Inc.

MGX Nasdaq Healthcare · Biological Products, (No Diagnostic Substances) Emeryville, CA metagenomi.co
$0.72
Mkt Cap 27.0M

Developer of in vivo genome-editing therapies intended to cure genetic diseases; no approved products yet.

metagenomi.co ↗Summary by The Compound Family, based on the company’s own website
—
/100 Overall
Calculating score…
Running full analysis
Ready to value this company?
Run a full DCF model with Monte Carlo simulation.
Run DCF Valuation →
📊 Key Metrics
Loading full analysis…
REVENUE TTM
$22.3M
-24.9% CAGR
FCF TTM
-$87.5M
-392% margin
Running full 6-factor analysis…